GGrantIndex
← Leaderboards

Jay S Schneider

Thomas Jefferson University

$22,871,022
Attributed
$24,307,949
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,307,949 · 11

By mechanism

R01$22,592,624 · 8
U10$1,122,225 · 1
R21$429,000 · 1
R56$164,100 · 1

Top collaborators

Most similar at Thomas Jefferson University

Same institution · by research overlap

Others in their field

Top investigators on “Lead

Research focus

LeadBehavioralResponseMemoryAffectBrainCognitiveLead ExposureFemaleMaleBaseAnimalsBehaviorBrain BehaviorLearningCognitive DeficitsExposure ToBlood LeadGene ExpressionMethylationDna MethylationMediatingChildGenes

Grant awards (63)

The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure$549,132
R01 · FY2025 · ES · contact PI
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure$27,749
R01 · FY2025 · ES · contact PI
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure$549,134
R01 · FY2024 · ES · contact PI
Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure$516,017
R01 · FY2024 · ES · contact PI
Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure$516,017
R01 · FY2023 · ES · contact PI
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure$515,436
R01 · FY2023 · ES · contact PI
Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure$516,017
R01 · FY2022 · ES · contact PI
Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure$516,017
R01 · FY2021 · ES · contact PI
Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure$467,663
R01 · FY2020 · ES · contact PI
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure.$164,100
R56 · FY2019 · ES · contact PI
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$413,718
R01 · FY2017 · ES
Environment and Gene Effects on Brain and Behavior$401,160
R01 · FY2017 · ES · contact PI
Environment and Gene Effects on Brain and Behavior$473,195
R01 · FY2016 · ES · contact PI
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$468,468
R01 · FY2016 · ES
Retinal Imaging with Optical Coherence Tomography as a Biomarker for Manganese Neurotoxicity$195,000
R21 · FY2016 · ES · contact PI
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$538,849
R01 · FY2015 · ES
Environment and Gene Effects on Brain and Behavior$512,379
R01 · FY2015 · ES · contact PI
Retinal Imaging with Optical Coherence Tomography as a Biomarker for Manganese Neurotoxicity$234,000
R21 · FY2015 · ES · contact PI
Environment and Gene Effects on Brain and Behavior$435,944
R01 · FY2014 · ES · contact PI
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$425,639
R01 · FY2014 · ES
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$99,957
R01 · FY2014 · ES
Environment and Gene Effects on Brain and Behavior$451,655
R01 · FY2013 · ES · contact PI
CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects$350,342
R01 · FY2013 · ES
NIH Exploratory Trials in Parkinson's Disease (NET-PD): Clinical Site$90,071
U10 · FY2013 · NS · contact PI
Attention and Executive Functioning in Aging and Parkisonism$360,322
R01 · FY2012 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$350,626
R01 · FY2012 · ES · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$88,153
U10 · FY2012 · NS · contact PI
Attention and Executive Functioning in Aging and Parkisonism$458,529
R01 · FY2011 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$414,154
R01 · FY2011 · ES · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$103,530
U10 · FY2011 · NS · contact PI
Attention and Executive Functioning in Aging and Parkisonism$536,204
R01 · FY2010 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$409,308
R01 · FY2010 · ES · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$143,297
U10 · FY2010 · NS · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$85,200
U10 · FY2010 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$867,620
R01 · FY2009 · ES · contact PI
Attention and Executive Functioning in Aging and Parkisonism$449,283
R01 · FY2009 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$399,892
R01 · FY2009 · ES · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$124,303
U10 · FY2009 · NS · contact PI
Attention and Executive Functioning in Aging and Parkisonism$496,088
R01 · FY2008 · NS · contact PI
Environment and Gene Effects on Brain and Behavior$413,890
R01 · FY2008 · ES · contact PI
Nicotine and Cognition in Parkinsonism$368,737
R01 · FY2008 · DA · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$175,728
U10 · FY2008 · NS · contact PI
GM1 Ganglioside Effects on Parkinson's Disease$599,663
R01 · FY2007 · NS · contact PI
Nicotine and Cognition in Parkinsonism$376,263
R01 · FY2007 · DA · contact PI
Clinical Center: Parkinson's Disease Neuroprotection Trial$65,391
U10 · FY2007 · NS · contact PI
GM1 Ganglioside Effects on Parkinson's Disease$927,279
R01 · FY2006 · NS · contact PI
Nicotine and Cognition in Parkinsonism$380,407
R01 · FY2006 · DA · contact PI
Clinical Center: Parkinson's Disease Neuroprotection$11,400
U10 · FY2006 · NS · contact PI
GM1 Ganglioside Effects on Parkinson's Disease$1,229,870
R01 · FY2005 · NS
Nicotine and Cognition in Parkinsonism$318,000
R01 · FY2005 · DA
GM1 Ganglioside Effects on Parkinson's Disease$793,319
R01 · FY2004 · NS
Nicotine and Cognition in Parkinsonism$357,750
R01 · FY2004 · DA
GM1 GANGLIOSIDE EFFECTS ON PARKINSONS DISEASE$460,817
R01 · FY2003 · NS
Nicotine and Cognition in Parkinsonism$397,500
R01 · FY2003 · DA
Clinical Center: Parkinson's Disease Neuroprotection$119,757
U10 · FY2003 · NS
GM1 GANGLIOSIDE EFFECTS ON PARKINSONS DISEASE$19,625
R01 · FY2003 · NS
GM1 GANGLIOSIDE EFFECTS ON PARKINSONS DISEASE$488,445
R01 · FY2002 · NS
Nicotine and Cognition in Parkinsonism$397,500
R01 · FY2002 · DA
Clinical Center: Parkinson's Disease Neuroprotection$115,395
U10 · FY2002 · NS
GM1 GANGLIOSIDE EFFECTS ON PARKINSONS DISEASE$474,062
R01 · FY2001 · NS
Nicotine and Cognition in Parkinsonism$354,417
R01 · FY2001 · DA
GM1 GANGLIOSIDE EFFECTS ON PARKINSONS DISEASE$491,158
R01 · FY2000 · NS
NEUROBEHAVIORAL PLASTICITY AFTER DOPAMINE SYSTEM DAMAGE$257,408
R01 · FY2000 · NS